Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2025 13:07 ET | Source: BCC Research LLC

Viral Vector Market to Grow 24.6% Annually Through 2030

The report segments the market by type, application and disease including adenoviral vectors, adeno-associated viral vectors, lentiviral vectors etc.
December 16, 2025 08:40 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies,...
December 15, 2025 08:30 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic...
December 11, 2025 07:30 ET | Source: Autobahn Labs

Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines

Autobahn Labs and Astellas form a strategic partnership to source and develop early-stage drug discovery programs from academia.
December 04, 2025 08:00 ET | Source: Beghou

Beghou Adds New Partners to Advance Integrated, Experience-Driven Commercialization in Life Sciences

Beghou adds new partners Jenny Herritz and Marcos Mendell to help drive more connected, experience-driven life sciences commercialization efforts.
December 02, 2025 08:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the...
December 01, 2025 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

These patents represent a significant turning point for Propanc and commercial potential of PRP for treating chronic diseases such as cancer and fibrosis
November 28, 2025 07:01 ET | Source: AbbVie Canada

L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne

SKYRIZI®, un inhibiteur de l’interleukine 23 (IL-23), a fait l’objet de deux recommandations consécutives de l’Agence des médicaments du Canada (AMC) visant son remboursement pour le traitement des...
November 28, 2025 07:01 ET | Source: AbbVie Canada

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s...
November 26, 2025 07:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...